Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
devimistat + FOLFIRINOX + bevacizumab
- Development stage
- Unknown
- Lead developer
- Cornerstone Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen consisting of **devimistat** (a novel lipoate analog that inhibits enzymes involved in mitochondrial energy metabolism), **FOLFIRINOX** (a chemotherapy regimen comprising folinic acid [leucovorin], fluorouracil, irinotecan, and oxaliplatin), and **bevacizumab** (a humanized monoclonal antibody targeting vascular endothelial growth factor A [VEGF-A]). Devimistat inhibits the pyruvate dehydrogenase complex and alpha-ketoglutarate dehydrogenase, disrupting abnormal mitochondrial metabolism in tumor cells. FOLFIRINOX combines antimetabolite, topoisomerase I inhibitor, and platinum-based cytotoxic drugs. Bevacizumab inhibits angiogenesis by neutralizing VEGF-A, limiting tumor vascularization. This multi-agent regimen is used in investigational settings for cancers such as advanced pancreatic cancer, aiming at metabolic inhibition, cytotoxicity, and anti-angiogenesis.
- Other names
- CPI-613 + FOLFIRINOX + bevacizumab
02
Targets
α-KGDH (Alpha-ketoglutarate dehydrogenase complex)TS (Thymidylate synthase)PDH (Pyruvate dehydrogenase complex)DNATOP1 (DNA Topoisomerase I)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on devimistat + FOLFIRINOX + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on devimistat + FOLFIRINOX + bevacizumab.